Goldman Sachs Group Inc Clearside Biomedical, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.08 - $1.83 $1,964 - $3,328	-1,819 Reduced 8.61%	19,308 $22,000
Q3 2022 Nov 10, 2022	SELL	$1.08 - $1.83 $1,964 - $3,328	-1,819 Reduced 8.61%	19,308 $0
Q2 2022 May 14, 2024	BUY	$1.3 - $2.49 $27,465 - $52,606	21,127 New	21,127 $31,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $19,784 - $37,895	-15,219 Reduced 41.87%	21,127 $31,000
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $58,206 - $124,174	-43,116 Reduced 54.26%	36,346 $84,000
Q4 2021 Feb 14, 2022	BUY	$2.72 - $5.72 $88,797 - $186,735	32,646 Added 69.73%	79,462 $219,000
Q3 2021 Nov 10, 2021	BUY	$4.83 - $7.2 $226,121 - $337,075	46,816 New	46,816 $281,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.